Hospital Marina Baixa De La Vila Joiosa
- Address
- lock Available on a paid plan
Immune System Diseases
The Hospital Marina Baixa De La Vila Joiosa conducts research on disorders where the immune system attacks the body, including Systemic Lupus Erythematosus and Rheumatoid Arthritis. Trials aim to evaluate new biologic agents and compare safety profiles of emerging therapies.
- Belimumab efficacy in early lupus
- Baricitinib versus TNF inhibitors for joint disease
- Immune modulation strategies across autoimmune conditions
The goal is to improve disease control and reduce complications by testing innovative treatments that target immune pathways.
Skin and Connective Tissue Diseases
Studies at the site focus on chronic skin conditions such as Atopic Dermatitis, Plaque Psoriasis, and Nummular Eczema. Research evaluates both topical and systemic therapies to enhance skin clearance and quality of life.
- Ruxolitinib cream for moderate atopic dermatitis
- Adjusted brodalumab dosing for heavy patients with severe psoriasis
- Lebrikizumab effectiveness in nummular eczema
These trials seek to determine the safety and efficacy of novel agents, offering alternatives for patients who have not responded to standard treatments.
Virus Diseases
The department runs several investigations targeting HIV and HIV‑1 infection, focusing on long‑term viral suppression and treatment simplification for diverse patient groups.
- DTG/3TC maintenance therapy compared with standard regimens
- Long‑acting cabotegravir plus rilpivirine in adults over 60
- Switch strategies to injectable therapies for stable patients
The purpose is to assess new therapeutic options that maintain viral control while reducing pill burden and side effects.
Immune System Phenomena
Research also explores fundamental immune system phenomena that underlie multiple diseases, linking insights from dermatology and rheumatology to viral immunity.
- Cytokine inhibition across psoriasis and ulcerative colitis
- JAK pathway targeting in atopic dermatitis
- Biomarker studies to predict treatment response
By deciphering immune mechanisms, the site aims to guide the development of precision medicines for a range of inflammatory and infectious conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 5 therapeutic areas and 15 of 21 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Janssen Cilag International1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International3trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hospital Marina Baixa De La Vila Joiosa
lock Showing 1 of 13 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult Subjects with Axial Spondyloarthritis Followed by a Remission-Withdrawal Period | AbbVie Deutschland GmbH & Co. KG | Phase III | Not Recruiting | Mar 2020 | Apr 2024 |
IMP list
lock Showing 1 of 21 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Adalimumab | 2 | Unknown | 2019-07-25 | 2023-11-07 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.